Dementia and Alzheimer Disease

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

The Cleveland Clinic researcher described the 2-fold potential use for how his predictive Parkinson disease dementia model may be used pending the success of the study.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center detailed the promise marked by the results of a recent pilot trial of riluzole in Alzheimer disease.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine detailed the ongoing research in developing gene therapy for patients with Alzheimer disease.

Here's what is coming soon to NeurologyLive.

The use of real-time quaking-induced conversion and protein misfolding cyclic amplification assays accurately allowed researchers to differentiate synucleinopathies from nonsynucleinopathies.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine detailed the ongoing research in developing gene therapy for patients with Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center detailed the findings of a recent pilot trial of riluzole in Alzheimer disease she and colleagues conducted.

To date, the connection between vascular dysfunction and tau pathology and how it affects cognition has not been well understood.

The Cleveland Clinic researcher details a study that will use biomarkers to develop a predictive model to identify individuals with Parkinson disease who may develop dementia.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center discussed the literature that influenced a pilot trial of riluzole in Alzheimer disease.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 10, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Costantino Iadecola, MD.

Phase 2 results demonstrated proof-of-concept for treatment with neflamapimod, suggesting the need for a phase 3 study in the coming future.

The 5-year grant will support a research project that will use biomarkers to develop a predictive mathematical model to identify specific individuals with Parkinson disease who may develop dementia.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, discussed the strides made in Alzheimer disease research and the importance of diversity in research populations.

Linear mixed effects models revealed that anticholinergic medications predicted a steeper slope of decline in memory and language with effects exacerbated in individuals with Alzheimer disease risk factors.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 2, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.